Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
Flat design illustration of a drug compound and clinical trial symbol

Jul 17, 2026

How well are AI-discovered drugs faring in the clinic?

The integration of AI in drug discovery is still in its nascent stages, with mixed results in clinical trials. While AI has the potential to revolutionize the pharmaceutical landscape, the journey from AI-driven discovery to clinical success is fraught with challenges.AI has emerged as a promising tool for accelerating drug research and development, traditionally a lengthy and expensive process. Although some AI-discovered drugs have shown early promise in phase 1 trials, their performance in la
A minimalist representation of a biological sample in a dark color scheme.

Jul 17, 2026

Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform

Sightera Biosciences, a startup based in Antwerp, has successfully secured €3 million in pre-Seed funding to enhance its AI-driven drug discovery platform, which focuses on patient-derived biological data. This financing round was led by Entourage, Anacura, and QBIC, and the company aims to expand its team and accelerate the development of its oncology and fibrosis programs.The innovative approach of Sightera lies in its unique training methodology for its AI models. Instead of relying on generi
A test tube with antibody solution on a lab table

Jul 17, 2026

Argenx Partners With Chai Discovery for AI Antibody...

Chai Discovery has partnered with argenx to leverage AI for antibody discovery, marking a significant advancement in the life sciences sector.Chai Discovery, based in San Francisco, has formed a collaboration with argenx, providing the immunology firm with early access to its generative AI platform aimed at de novo antibody discovery. This partnership is notable as it is the fourth disclosed collaboration for Chai within a span of seven months, following similar agreements with major pharmaceuti
A close-up of an organoid culture dish in a dimly lit lab, highlighting the intricate details of the tissue sample.

Jul 17, 2026

Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first

Belgian biotech Sightera Biosciences has secured €3 million in pre-seed funding to advance its innovative AI drug discovery platform, which uniquely focuses on learning from treatment-resistant patients.Sightera's approach diverges from conventional AI drug discovery methods by starting with data from patients who do not respond to standard treatments. This "extreme biology" strategy involves creating organoids from these patients' tissues and conducting high-throughput drug screenings to gather
A minimalist illustration of a surgical robot arm and scalpel on a dark background.

Jul 16, 2026

Japan overhauls healthcare and life sciences with Nvidia AI

Japan is set to revolutionize its healthcare and life sciences sectors through the integration of AI technologies, particularly leveraging Nvidia's innovations.Recent discussions led by Nvidia CEO Jensen Huang highlighted Japan's commitment to advancing medical technology with AI-driven solutions. The country is actively implementing autonomous surgical robots, AI-enhanced imaging systems, and innovative drug discovery platforms. A notable initiative is the Tokyo-1 consortium, which unites major
A laboratory vial containing a drug compound in a dimly lit lab setting.

Jul 15, 2026

Bora Pharmaceuticals and Insilico Medicine Strike a $2.5 Billion AI Alliance

Bora Pharmaceuticals and Insilico Medicine have entered a significant partnership aimed at revolutionizing AI-driven drug development, with a potential value exceeding $2.5 billion.This collaboration, announced during BIO Asia-Taiwan, marks a pivotal shift in the pharmaceutical landscape, focusing on integrating AI not just in drug discovery but also in manufacturing processes. Insilico's Pharma.AI platform, which encompasses tools for target discovery and clinical insights, will be paired with
A minimalist representation of a TNIK inhibitor molecule in a dark color scheme.

Jul 15, 2026

Insilico & Bora Partner on AI Drug Discovery

Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance aimed at enhancing AI-driven drug discovery and development.The partnership leverages Insilico's Pharma.AI platform, which integrates target identification, generative chemistry, and multi-parameter optimization. Since its inception in 2021, this platform has successfully generated 31 preclinical candidates, with 13 receiving IND approvals. Notably, one standout asset is ISM018_055, an AI-generated TNIK inhibitor current
A vial of a drug compound in a dimly lit laboratory setting.

Jul 15, 2026

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Insilico Medicine and Bora Pharmaceuticals are poised to form a strategic alliance aimed at revolutionizing drug discovery and development through AI technologies.The proposed collaboration is anticipated to be valued at over $2.5 billion if fully realized. It aims to integrate Insilico's Pharma.AI platform—which specializes in target discovery, generative chemistry, and molecule optimization—with Bora's extensive capabilities in drug development, manufacturing, and commercialization. This partn
A minimalist illustration of a pill bottle and an AI chip on a dark background.

Jul 15, 2026

Bora, Insilico Launch Multi-Target AI Pharma Alliance

Insilico Medicine has formed a strategic alliance with Bora Pharmaceuticals to integrate AI into drug discovery and development.Insilico Medicine, known for its generative AI-driven approach to drug discovery, has partnered with Bora Pharmaceuticals to create a multi-target alliance. This collaboration aims to merge Insilico’s Pharma.AI platform with Bora’s extensive capabilities in global development, manufacturing, and commercialization. The goal is to innovate drug development by linking AI-e
A molecule in a petri dish in a dimly lit lab

Jul 15, 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine has announced a strategic alliance with Bora Pharmaceuticals aimed at revolutionizing drug discovery through AI integration.The partnership will leverage Insilico's Pharma.AI platform, which encompasses target discovery and molecule optimization, alongside Bora's extensive capabilities in drug development and manufacturing. This collaboration aspires to create a comprehensive model that not only designs novel molecules but also streamlines their development and delivery to addr
A vial of a drug compound in a dimly lit laboratory setting

Jul 15, 2026

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Miles Wang, an OpenAI researcher known for his contributions to AI in scientific discovery, is reportedly leaving the organization to establish a new startup dedicated to AI-driven drug discovery. This venture is anticipated to be valued at $2 billion, with plans to raise approximately $200 million, primarily led by Lightspeed Venture Partners.The proposed startup aims to leverage AI models to enhance the drug discovery process, potentially identifying new applications for existing medications,
A minimalist representation of a drug molecule in flat design.

Jul 15, 2026

OpenAI Researcher Miles Wang Eyes $2B AI Drug Discovery Startup

OpenAI researcher Miles Wang is poised to launch an AI-driven drug discovery startup valued at $2 billion, marking a significant trend in biotech investment.Wang's venture is reportedly in advanced discussions with Lightspeed Venture Partners, which aims to lead a funding round that could become one of the largest in the biotech sector. This initiative highlights the growing investor confidence in AI's ability to transform pharmaceutical development, particularly in drug discovery, which traditi